Condition
Chronic Beryllium Disease
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Completed2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06113991Unknown
Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis
NCT02604693CompletedPrimary
Exposure in Epigenetic Regulation of Immune Response in Chronic Beryllium Disease (CBD)
NCT01088243Phase 1CompletedPrimary
Targeting Oxidative Stress in Chronic Beryllium Disease
Showing all 3 trials